Infinity Pharmaceuticals Inc (INFI)

NASDAQ
3.380
-0.250(-6.89%)
Pre Market
3.400
+0.020(+0.59%)
- Real-time Data
  • Volume:
    1,949,901
  • Bid/Ask:
    3.350/3.400
  • Day's Range:
    3.360 - 3.520
  • Type:Equity
  • Market:United States
  • ISIN:US45665G3039
  • CUSIP:00045665G303

INFI Overview

Prev. Close
3.63
Day's Range
3.36-3.52
Revenue
1.92M
Open
3.42
52 wk Range
1-5.96
EPS
-0.6
Volume
1,949,901
Market Cap
299.87M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
7,488,525
P/E Ratio
-
Beta
2.19
1-Year Change
207.27%
Shares Outstanding
88,719,539
Next Earnings Date
Nov 09, 2021
What is your sentiment on Infinity Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Infinity Pharmaceuticals Inc News

Infinity Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellSellStrong Buy

Infinity Pharmaceuticals Inc Company Profile

Infinity Pharmaceuticals Inc Company Profile

Employees
23

Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.

Read More
  • Bought 2.47 going for double
    0
    • $9 by the end of this month
      10
      • Any more predcitions?
        0
    • any news ..updates?
      1
      • any news or updates...buy sell hold?
        0
        • offering at 3,80
          0
        • what does that mean
          0
      • what is the marketabiliity of the product to generate income?
        0
        • Why did I buy this....ugh.
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.